A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response
Authors
Keywords
-
Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 203, Issue 7, Pages 960-968
Publisher
Oxford University Press (OUP)
Online
2011-03-14
DOI
10.1093/infdis/jiq138
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
- (2010) Steven A Yukl et al. AIDS
- Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy
- (2010) D. McMahon et al. CLINICAL INFECTIOUS DISEASES
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
- (2010) Maria J Buzón et al. NATURE MEDICINE
- The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
- (2010) Rajesh T. Gandhi et al. PLOS MEDICINE
- Incomplete Peripheral CD4+Cell Count Restoration in HIV‐Infected Patients Receiving Long‐Term Antiretroviral Treatment
- (2009) Colleen F. Kelley et al. CLINICAL INFECTIOUS DISEASES
- Detection of HIV-1 in alternative specimen types using the APTIMA® HIV-1 RNA Qualitative Assay
- (2009) C. Thomas Nugent et al. JOURNAL OF VIROLOGICAL METHODS
- HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy
- (2009) Maud Mavigner et al. PLoS One
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
- (2009) J. B. Dinoso et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
- (2008) Jason V Baker et al. AIDS
- Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control
- (2008) A. L. Ferre et al. BLOOD
- Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia
- (2008) Flavien Bernardin et al. HEPATOLOGY
- Collagen Deposition Limits Immune Reconstitution in the Gut
- (2008) Jacob Estes et al. JOURNAL OF INFECTIOUS DISEASES
- Genetic and Immunologic Heterogeneity among Persons Who Control HIV Infection in the Absence of Therapy
- (2008) Florencia Pereyra et al. JOURNAL OF INFECTIOUS DISEASES
- Persistence of HIV in Gut‐Associated Lymphoid Tissue despite Long‐Term Antiretroviral Therapy
- (2008) Tae‐Wook Chun et al. JOURNAL OF INFECTIOUS DISEASES
- Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy
- (2008) H. Hatano et al. JOURNAL OF VIROLOGY
- Magnitude and Complexity of Rectal Mucosa HIV-1-Specific CD8+ T-Cell Responses during Chronic Infection Reflect Clinical Status
- (2008) J. William Critchfield et al. PLoS One
- Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
- (2008) S. Palmer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection
- (2008) Lewis H Kuller et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started